inclusion criteria: to be eligible for the study, each participant must satisfy all of the following criteria: 1. male and female healthy adults ages 18 years of age or older; 2. good general health as determined by screening evaluation no greater than 30 days before immunization; 3. if female of child-bearing potential and heterosexually active, practice of adequate contraception for 30 days prior to injection, negative pregnancy test on the day of injection, and agreement to continue adequate contraception until 180 days after the second injection and; 4. written informed consent, after review of the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee.

inclusion criteria: to be eligible for the study, each participant must satisfy all of the following criteria: 1. male and female healthy adults ages 18 years of age or older; 2. good general health as determined by screening evaluation no greater than 30 days before immunization; 3. if female of child-bearing potential and heterosexually active, practice of adequate contraception for 30 days prior to injection, negative pregnancy test on the day of injection, and agreement to continue adequate contraception until 180 days after the second injection and; 4. written informed consent, after review of the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee.

inclusion criteria: to be eligible for the study, each participant must satisfy all of the following criteria: male and female healthy adults ages 18 years of age or older; good general health as determined by screening evaluation no greater than 30 days before immunization; if female of child-bearing potential and heterosexually active, practice of adequate contraception for 30 days prior to injection, negative pregnancy test on the day of injection, and agreement to continue adequate contraception until 180 days after the second injection and; written informed consent, after review of the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee.

inclusion criteria: to be eligible for the study, each participant must satisfy all of the following criteria: male and female healthy adults ages 18 years of age or older; good general health as determined by screening evaluation no greater than 30 days before immunization; if female of child-bearing potential and heterosexually active, practice of adequate contraception for 30 days prior to injection, negative pregnancy test on the day of injection, and agreement to continue adequate contraception until 180 days after the second injection and; written informed consent, after review of the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee.

inclusion criteria: to be eligible for the study, each participant must satisfy all of the following criteria: 1. male and female healthy adults ages 18 years of age or older; 2. good general health as determined by screening evaluation no greater than 30 days before immunization; 3. if female of child-bearing potential and heterosexually active, practice of adequate contraception for 30 days prior to injection, negative pregnancy test on the day of injection, and agreement to continue adequate contraception until 180 days after the second injection and; 4. written informed consent, after review of the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee.

inclusion criteria: to be eligible for the study, each participant must satisfy all of the following criteria: 1. male and female healthy adults ages 18 years of age or older; 2. good general health as determined by screening evaluation no greater than 30 days before immunization; 3. if female of child-bearing potential and heterosexually active, practice of adequate contraception for 30 days prior to injection, negative pregnancy test on the day of injection, and agreement to continue adequate contraception until 180 days after the second injection and; 4. written informed consent, after review of the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee.